These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 11679181)

  • 1. Identification of HER-2/neu overexpression and the clinical course of lung carcinoma in non-smokers with chronic lymphocytic leukemia.
    Potti A; Ganti AK; Koch M; Mehdi SA; Levitt R
    Lung Cancer; 2001 Nov; 34(2):227-32. PubMed ID: 11679181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of prognostic implications of HER-2/neu abnormalities in 345 stage I non-small cell carcinomas (NSCLC) and 207 stage I-III neuroendocrine tumours (NET) of the lung.
    Pelosi G; Del Curto B; Dell'Orto P; Pasini F; Veronesi G; Spaggiari L; Maisonneuve P; Iannucci A; Terzi A; Lonardoni A; Viale G
    Int J Cancer; 2005 Jan; 113(1):101-8. PubMed ID: 15386424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical course of lung carcinoma in patients with chronic lymphocytic leukemia.
    Parekh K; Rusch V; Kris M
    Cancer; 1999 Nov; 86(9):1720-3. PubMed ID: 10547544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER-2/neu protein expression and gene alteration in stage I-IIIA non-small-cell lung cancer: a study of 140 cases using a combination of high throughput tissue microarray, immunohistochemistry, and fluorescent in situ hybridization.
    Tan D; Deeb G; Wang J; Slocum HK; Winston J; Wiseman S; Beck A; Sait S; Anderson T; Nwogu C; Ramnath N; Loewen G
    Diagn Mol Pathol; 2003 Dec; 12(4):201-11. PubMed ID: 14639106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study of pretreatment serum levels of HER-2/neu oncoprotein as a prognostic and predictive factor in patients with advanced nonsmall cell lung carcinoma.
    Ardizzoni A; Cafferata MA; Paganuzzi M; Filiberti R; Marroni P; Neri M; Fontana V; Nicoló G; Perdelli L; Stampino CG; Rosso R; Puntoni R
    Cancer; 2001 Oct; 92(7):1896-904. PubMed ID: 11745263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive role of HER-2/neu overexpression and clinical features at initial presentation in patients with extensive stage small cell lung carcinoma.
    Potti A; Willardson J; Forseen C; Kishor Ganti A; Koch M; Hebert B; Levitt R; Mehdi SA
    Lung Cancer; 2002 Jun; 36(3):257-61. PubMed ID: 12009234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER-2/neu expression in archival non-small cell lung carcinomas using FDA-approved Hercep test.
    Scheurle D; Jahanzeb M; Aronsohn RS; Watzek L; Narayanan R
    Anticancer Res; 2000; 20(3B):2091-6. PubMed ID: 10928158
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of pesticide exposure on HER-2/neu overexpression seen in patients with extensive stage small cell lung carcinoma.
    Potti A; Ganti AK; Sholes K; Langness E; Koka V; Horvarth L; Koch M
    Clin Cancer Res; 2003 Oct; 9(13):4872-6. PubMed ID: 14581360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer.
    Han H; Landreneau RJ; Santucci TS; Tung MY; Macherey RS; Shackney SE; Sturgis CD; Raab SS; Silverman JF
    Hum Pathol; 2002 Jan; 33(1):105-10. PubMed ID: 11823980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of HER-2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be the method of choice?
    Sauer T; Wiedswang G; Boudjema G; Christensen H; Karesen R
    APMIS; 2003 Mar; 111(3):444-50. PubMed ID: 12752225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival.
    Selvaggi G; Scagliotti GV; Torri V; Novello S; Leonardo E; Cappia S; Mossetti C; Ardissone F; Lausi P; Borasio P
    Cancer; 2002 May; 94(10):2669-74. PubMed ID: 12173335
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification and relationship of HER-2/neu overexpression to short-term mortality in primary malignant brain tumors.
    Forseen SE; Potti A; Koka V; Koch M; Fraiman G; Levitt R
    Anticancer Res; 2002; 22(3):1599-602. PubMed ID: 12168843
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas.
    Hirsch FR; Varella-Garcia M; Franklin WA; Veve R; Chen L; Helfrich B; Zeng C; Baron A; Bunn PA
    Br J Cancer; 2002 May; 86(9):1449-56. PubMed ID: 11986780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical identification of HER-2/neu overexpression and CD117 (c-kit) expression in multiple myeloma.
    Potti A; Ganti AK; Koch M; Levitt R; Mehdi SA
    Leuk Lymphoma; 2002 Dec; 43(12):2427-30. PubMed ID: 12613538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of HER-2/neu overexpression and clinical predictors of survival in a cohort of 347 patients with primary malignant brain tumors.
    Potti A; Forseen SE; Koka VK; Pervez H; Koch M; Fraiman G; Mehdi SA; Levitt R
    Cancer Invest; 2004; 22(4):537-44. PubMed ID: 15565811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER-2/Neu alterations in non-small cell lung cancer: a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry.
    Pellegrini C; Falleni M; Marchetti A; Cassani B; Miozzo M; Buttitta F; Roncalli M; Coggi G; Bosari S
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3645-52. PubMed ID: 14506153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2/neu expression and amplification in non-small cell lung cancer prior to and after neoadjuvant therapy.
    Junker K; Stachetzki U; Rademacher D; Linder A; Macha HN; Heinecke A; Müller KM; Thomas M
    Lung Cancer; 2005 Apr; 48(1):59-67. PubMed ID: 15777971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Her-2/neu overexpression and clinical determinants of early mortality in glioblastoma multiforme.
    Koka V; Potti A; Forseen SE; Pervez H; Fraiman GN; Koch M; Levitt R
    Am J Clin Oncol; 2003 Aug; 26(4):332-5. PubMed ID: 12902879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.
    Khan AJ; King BL; Smith BD; Smith GL; DiGiovanna MP; Carter D; Haffty BG
    Clin Cancer Res; 2002 Feb; 8(2):540-8. PubMed ID: 11839675
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Her-2/neu gene amplification and protein expression in primary male breast cancer.
    Rudlowski C; Friedrichs N; Faridi A; Füzesi L; Moll R; Bastert G; Rath W; Büttner R
    Breast Cancer Res Treat; 2004 Apr; 84(3):215-23. PubMed ID: 15026619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.